Search Results

Amazentis, an innovative Swiss life sciences company pioneering scientific breakthroughs in nutrition, announced today the initiation of a randomized, double-blinded, placebo-controlled clinical trial in top athletes

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland

Amazentis Also Announces Initiation of Two Pivotal, Phase 2 Clinical Studies in North America

Nestlé Health Science today announced that it has entered into a global strategic partnership with Amazentis, a Swiss-based pioneer in science-driven nutritional health.

Mitopure™, a first-of-its kind cellular nutrient, clinically proven to boost cellular function and improve muscle strength, is now available to health-striving consumers in Timeline Nutrition products*.

Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA).

Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Metabolism with scientists at the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) demonstrating the Company’s lead product, Urolithin A (UA), is safe, bioavailable and improves mitochondrial and cellular health in humans.

Vandria SA announced that it has been awarded two grants totalling €3.8M from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively.

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, emerged from stealth with the announcement of its successful Series A fundraise.